Abstract 278P
Background
Burkitt Lymphoma (BL) is a rare and aggressive type of non-Hodgkin lymphoma (NHL), accounting for 0.8% of all B-cell lymphomas, with five-year survival ranging from 48% to 87%. Currently, intensive short-cycle and low-intensity multiagent immunochemotherapy regimens are used, however, it is not clear what health economic evidence exists for treatments in BL. Thereby, a systematic literature review (SLR) was conducted to understand the economic (costs and resource-use, economic evaluations) evidence base for patients with BL.
Methods
An SLR was conducted using Embase®, PubMed®, and EconLit from database inception through June 2019.
Results
A total of 758 abstracts and 132 full-texts were screened. We identified 2 economic evaluations and 7 studies reporting data for costs or resource-use covering four countries (Malawi, Nigeria, Uganda, Netherlands). The economic evidence varied in different regions due to unbalanced socio-economic development. The median length of hospital stay ranged from 13 days in Nigeria to 134 days in the Netherlands. The patients were also reluctant to healthcare and took 4-8 weeks from the onset of symptoms to present at the treatment centers in Nigeria. The total direct cost of treating BL was US$103.8 (Nigeria), US$350.14 (Uganda), and US$7342.17 (Netherlands) per patient. Dominant drivers for cost were the length of in-hospital stay and medication costs. Both the economic evaluations presented models for paediatric patients with no treatment as the comparator of choice and a continuous discount rate of 3%. Models were built from a governmental perspective with discounting and duration of treatment significantly impacting the sensitivity analysis. The cost per DALY averted was US$97 in Uganda and US$14,243 in Malawi, reflecting very cost-effective chemotherapeutic interventions.
Conclusions
This review highlights the limited literature on the economic dimensions of BL treatment, however, also demonstrates cost-effective interventions in resource-limited settings. There remains a need for future research and careful consideration of BL as an investment in health systems strengthening and improving the health outcomes.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
15P - Comparing the outcomes of the mastectomy using the tumescent technique by between the special and non-special surgeons
Presenter: Naoya Takeda
Session: Poster display session
Resources:
Abstract
16P - Risk factors and prognostic value of non-alcoholic fatty liver disease (NAFLD) in hormone positive, non-metastatic breast cancer receiving adjuvant hormonal therapy
Presenter: Kartika Taroeno Hariadi
Session: Poster display session
Resources:
Abstract
17P - Distance related outcome in indigenous and non-indigenous breast cancer women of Western Australia
Presenter: Azim Khan
Session: Poster display session
Resources:
Abstract
18P - Usefulness of neutrophil to lymphocyte ratio in early stage breast cancer as predictor of disease-free survival in a Babylon Oncology Center
Presenter: Yaala Raof Al-Bairmany
Session: Poster display session
Resources:
Abstract
19P - Silymarin functionalized quantum cores as selective inhibitor of polo-like kinase 1, and preclinical antitumor activity in human breast cancer xenografts
Presenter: Manickam Paulpandi
Session: Poster display session
Resources:
Abstract
20P - Diagnostic value of serum HER-2 level in compression with tissue HER-2 in breast cancer: A systematic review and meta-analysis
Presenter: Amir Shamshirian
Session: Poster display session
Resources:
Abstract
21P - Clinical outcome of treatment without trastuzumab in HER2 positive breast cancer patients
Presenter: Than Than Aye
Session: Poster display session
Resources:
Abstract
22P - Clinical outcomes after skin-sparing or nipple areolar complex-sparing mastectomy with sentinel lymph node biopsy in early breast cancer patients
Presenter: Hye Yoon Lee
Session: Poster display session
Resources:
Abstract
23P - The correlations between knowledge and attitudes of productive age women toward “SADARI” (breast self-assessment) as early detection of breast cancer in Pejeng Kaja Village, Ubud, Bali
Presenter: Yorky Brahmantya
Session: Poster display session
Resources:
Abstract
24TiP - KEYNOTE-756: A randomized, double-blind, phase III study of pembrolizumab or placebo with neoadjuvant chemotherapy and adjuvant endocrine therapy for high-risk, early-stage, ER+/HER2−breast cancer
Presenter: Fatima Cardoso
Session: Poster display session
Resources:
Abstract